Selank

Selank Peptide (TP-7) – GABAergic Signaling, Neuroimmune & Anxiety Research

Synthetic Tuftsin-Derived Heptapeptide for Experimental Neuroscience, Neurotransmission, Stress-Response Biology & Peptide Bioregulation

Selank, also known as TP-7, is a synthetic linear heptapeptide with the amino acid sequence Thr–Lys–Pro–Arg–Pro–Gly–Pro.

It was developed from tuftsin, an endogenous immunoregulatory tetrapeptide derived from immunoglobulin G. Selank contains the four-amino-acid tuftsin sequence followed by a C-terminal Pro–Gly–Pro extension.

Selank has been investigated in experimental neuroscience, behavioral pharmacology and neuroimmune research, particularly for its potential interactions with GABAergic neurotransmission, enkephalin metabolism and gene-expression pathways.

Its principal research areas include:

• GABAergic neurotransmission and receptor-associated signaling

• Experimental anxiety and stress-response models

• Tuftsin-derived peptide pharmacology

• Neuroimmune communication

• Enkephalin metabolism

• Gene expression in neural tissue

• Dopaminergic and serotonergic signaling research

• Neurotrophic and neuroplasticity-associated pathways

• Behavioral neuroscience

• Experimental cognitive research

• Peptide stability and enzymatic degradation

• Comparative neuropeptide pharmacology

Selank has been evaluated in laboratory studies, animal experiments and a limited number of human clinical studies, primarily conducted in Russia.

Although these studies have reported potentially interesting findings, the overall evidence base remains limited by study size, methodological reporting and a lack of large, independently replicated confirmatory trials.

Selank is not approved by the US FDA or the European Medicines Agency as a human medicine.

Regional clinical use of Selank does not establish the suitability of research-grade peptide products for medical administration.

ICAME Pharmacy Selank is intended strictly for laboratory research and development purposes. Not for human or veterinary use.

What Is Selank?

Selank is a synthetic peptide composed of seven amino acids.

Its sequence is:

Thr–Lys–Pro–Arg–Pro–Gly–Pro

The corresponding one-letter sequence is:

TKPRPGP

Selank belongs to a class of short regulatory peptides investigated for their interactions with neural and immune-associated biological systems.

Its design is based on the endogenous peptide tuftsin.

Tuftsin contains the sequence:

Thr–Lys–Pro–Arg

Selank extends this sequence by adding:

Pro–Gly–Pro

This extension was incorporated during the development of the peptide to modify its biological and metabolic properties.

The resulting compound is structurally distinct from tuftsin and should not be assumed to have identical activity.

Selank Molecular Structure

Selank is a linear heptapeptide containing seven amino acid residues connected by six peptide bonds.

Unlike cyclic peptides such as oxytocin, Selank does not contain an intramolecular disulfide bridge.

Molecular Characteristics

The molecular formula and mass describe the unmodified free peptide.

Research preparations containing acetate, residual water or other formulation components may have a different total material mass.

Selank Amino Acid Sequence

The sequence can be divided into two structural regions:

Tuftsin-derived region: Thr–Lys–Pro–Arg

C-terminal extension: Pro–Gly–Pro

This structure is important for understanding Selank's development and its relationship to endogenous immunoregulatory peptides.

Why Is the Pro–Gly–Pro Extension Important?

The C-terminal Pro–Gly–Pro sequence is an important feature of Selank's design.

Proline-containing peptide sequences can influence conformational flexibility and susceptibility to enzymatic degradation.

Researchers have investigated whether the extension changes the biological stability and duration of activity compared with tuftsin.

Research Topics

Proteolytic stability

Peptide degradation

Molecular conformation

Enzyme–substrate interactions

Peptide transport

Structure–activity relationships

However, a specific half-life or pharmacokinetic duration should not be assigned to every Selank preparation without supporting experimental evidence.

Scientific Background and Development

Selank was developed by researchers associated with the Institute of Molecular Genetics of the Russian Academy of Sciences and collaborating pharmacology institutions.

The peptide was designed as a synthetic analogue of tuftsin.

The development program explored the relationship between immune-derived peptides and nervous system function.

This research helped establish Selank as a subject of experimental studies involving anxiety-associated behavior, neurochemical signaling and immune responses.

Selank has also been used as a medicinal product in Russia for specific anxiety-related indications.

However, regional regulatory authorization is not equivalent to FDA or EMA approval.

Research-grade Selank supplied outside regulated pharmaceutical channels is not an approved clinical substitute.

How Does Selank Work?

Selank's complete molecular mechanism has not been conclusively established.

Several experimental mechanisms have been proposed.

These include:

Modulation of GABA-associated receptor binding

Changes in neurotransmission-related gene expression

Interactions with enkephalin-degrading enzyme systems

Alterations in immune-associated signaling

Effects on selected neurochemical pathways

No single universally accepted receptor mechanism fully explains Selank's reported biological effects.

Proposed Experimental Framework

Selank (TKPRPGP)

↓

Interaction With Neural or Immune-Associated Molecular Systems

↓

Changes in Receptor-Associated Signaling or Enzymatic Activity

↓

Altered Gene Expression and Cellular Responses

↓

Measured Outcomes in Experimental Models

This framework summarizes investigated mechanisms rather than a validated clinical pathway.

Selank and GABAergic Signaling

Gamma-aminobutyric acid, or GABA, is a major inhibitory neurotransmitter in the mammalian central nervous system.

GABAergic signaling helps regulate neuronal excitability and network activity.

Selank has been investigated for its interaction with GABA-associated signaling systems.

A 2018 experimental study examined Selank using radioligand binding methods.

The researchers reported that Selank influenced GABA-associated binding in brain membrane preparations and described findings consistent with positive allosteric modulation.

Important Scientific Distinction

These findings do not establish that Selank is a conventional direct GABA-A receptor agonist.

They also do not prove that Selank produces the same clinical effects as benzodiazepines.

Its pharmacology remains incompletely characterized.

Selank and GABA-A Receptor Research

GABA-A receptors are ligand-gated ion channels involved in inhibitory neurotransmission.

They are important targets in neuropharmacology.

Researchers have investigated whether Selank alters GABA-associated receptor interactions.

Research Areas

Radioligand binding

Receptor-associated allosteric effects

Neuronal inhibition

Receptor subunit biology

Neurotransmission-related gene expression

Comparative pharmacology

These experimental findings should not be interpreted as proof of a specific therapeutic mechanism in humans.

Selank and Benzodiazepine Research

Benzodiazepines are medicines that act as positive allosteric modulators at specific GABA-A receptor sites.

They have established clinical effects but also important safety considerations.

Selank has been compared with benzodiazepines in laboratory and limited clinical studies.

Some experiments investigated combined effects on GABA-associated binding.

Research Questions

Does Selank influence GABA-associated binding?

Are its effects dependent on receptor composition?

Does it interact with benzodiazepine-sensitive pathways?

Can its molecular effects be distinguished from conventional GABAergic medicines?

Are experimental findings reproducible?

Selank should not be described as a proven benzodiazepine replacement.

Selank and Gene Expression Research

Gene expression studies provide an important part of Selank's experimental evidence base.

A 2016 study investigated Selank-associated changes in genes involved in neurotransmission in rat frontal cortex.

The researchers evaluated expression changes in genes associated with:

GABA receptors

Neurotransmitter transporters

Ion channels

Dopamine receptors

Serotonin receptors

Other neural signaling components

The study reported changes in multiple genes following experimental exposure.

However, altered messenger RNA levels do not necessarily establish corresponding changes in protein activity, neuronal function or human clinical outcomes.

Selank and GABA-Related Gene Expression

The 2016 study compared the effects of Selank and GABA on neurotransmission-related gene expression.

The investigators reported partially overlapping patterns of gene-expression changes.

This suggested that Selank may interact with regulatory processes associated with GABAergic signaling.

Experimental Research Areas

GABA receptor subunit genes

Neurotransmitter transporter genes

Dopamine-associated genes

Serotonin-associated genes

Neuronal signaling networks

Time-dependent transcriptional responses

These findings were obtained in an animal model.

They should not be interpreted as proof of equivalent gene regulation in the human brain.

Selank and Anxiety Research

Anxiety involves complex interactions among neural circuits, neurotransmitters, hormonal systems and environmental factors.

Selank has been investigated in anxiety-associated behavioral models and small human studies.

Some clinical reports have described reductions in anxiety-related symptoms.

However, the overall evidence base remains limited.

Research Areas

Anxiety-associated behavior

Stress-response signaling

GABAergic neurotransmission

Autonomic responses

Behavioral pharmacology

Neuropeptide modulation

Neurochemical adaptation

Selank is not an FDA- or EMA-approved treatment for generalized anxiety disorder.

Selank and Generalized Anxiety Disorder Research

A 2008 Russian clinical publication reported a study involving 62 participants with generalized anxiety disorder or neurasthenia.

The study compared Selank with medazepam.

Thirty participants received Selank, while 32 received medazepam.

The investigators reported improvements in anxiety-associated measures.

They also examined enkephalin-associated biological endpoints.

Important Limitations

The published abstract does not provide enough methodological detail to independently evaluate all aspects of trial quality.

The study was relatively small.

A placebo-controlled comparison was not described in the abstract.

Independent replication in larger, rigorously controlled international trials is needed.

The study does not establish Selank as a universally effective or approved anxiety treatment.

Selank and Stress-Response Research

Stress responses involve interactions among the nervous, endocrine and immune systems.

Selank has been investigated in experimental stress-related contexts.

Potential Research Endpoints

Behavioral stress responses

Neurotransmission-associated signaling

Autonomic regulation

Neuroimmune interactions

Stress-associated gene expression

Neuropeptide metabolism

However, experimental changes in stress-related markers do not establish clinical efficacy for chronic stress or stress-related disorders.

Selank and Enkephalin Research

Enkephalins are endogenous opioid peptides involved in neurotransmission and pain-related signaling.

Their biological activity is influenced by enzymatic degradation.

Selank has been investigated for its effects on enzymes involved in enkephalin metabolism.

Some experimental studies have reported altered enkephalin degradation in biological preparations.

Research Topics

Enkephalin-degrading enzymes

Peptide metabolism

Endogenous opioid signaling

Neuropeptide stability

Neurochemical interactions

Enzyme inhibition

However, these findings do not establish that Selank acts as an opioid drug or produces clinically meaningful analgesia.

Selank and the Endogenous Opioid System

The endogenous opioid system includes peptides such as enkephalins, endorphins and dynorphins.

These molecules participate in neural signaling.

Selank's reported interactions with enkephalin metabolism provide a possible research connection to this system.

However, direct opioid receptor agonism has not been established as Selank's defining mechanism.

Selank should not be classified as an established opioid analgesic.

Selank and Neuroimmune Research

One of Selank's distinctive research areas is neuroimmune communication.

The nervous and immune systems interact through multiple molecular pathways.

Tuftsin, the parent peptide used in Selank's design, is associated with immune regulation.

This background has encouraged investigation of Selank in immune-associated experimental models.

Research Areas

Immune cell signaling

Cytokine-associated responses

Gene expression

Neuroimmune communication

Immune-associated peptide biology

Inflammatory signaling

Stress–immune interactions

However, Selank's immune-related effects may vary between cell types and experimental conditions.

Selank and Cytokine Research

Cytokines are signaling molecules involved in immune regulation.

A 2008 study examined Selank in patients with anxiety-asthenic disorders and in laboratory experiments involving peripheral blood cells.

The investigators reported changes in selected immune-associated endpoints, including interleukin-6-related responses and cytokine balance.

Important Limitation

Changes in cytokine measurements do not establish that Selank improves immune function or prevents infection.

The study findings require replication and careful interpretation.

Selank is not an established immune-boosting treatment.

Selank and Interleukin-6

Interleukin-6, or IL-6, participates in multiple immune and inflammatory processes.

Its biological effects depend on cellular context.

Selank has been investigated in experimental systems measuring IL-6-related responses.

Some reported findings differed between cells obtained from patient groups and healthy controls.

This illustrates the importance of biological context.

Selank should not be described as uniformly increasing or suppressing IL-6 in all tissues.

Selank and Neuroinflammation Research

Neuroinflammation involves signaling among neurons, microglia, astrocytes and immune-associated cells.

Selank's neuroimmune research background makes it relevant to exploratory studies of these processes.

Potential Research Areas

Inflammatory signaling

Immune-associated gene expression

Neural stress responses

Cytokine regulation

Cellular communication

Neuroimmune adaptation

However, Selank has not been established as a clinically effective treatment for neuroinflammatory diseases.

Selank and Dopaminergic Signaling

Dopamine is involved in movement, motivation, reward processing and other nervous system functions.

Selank-related gene-expression research has included dopamine receptor-associated genes.

Some animal experiments reported changes in expression of selected dopaminergic markers.

Research Topics

Dopamine receptor gene expression

Neurotransmission

Reward-associated signaling

Behavioral responses

Neural adaptation

Gene regulatory networks

However, these findings do not establish that Selank reliably increases dopamine levels in humans.

Selank and Serotonergic Signaling

Serotonin participates in mood-associated, sensory and physiological processes.

Some Selank studies have examined serotonin-related gene expression.

Potential research areas include:

Serotonin receptor genes

Neurotransmission

Stress-associated signaling

Behavioral neuroscience

Gene-expression responses

However, Selank is not an established selective serotonin reuptake inhibitor or conventional serotonergic medicine.

Its effects on human serotonin signaling remain insufficiently characterized.

Selank and Neurotrophic Research

Neurotrophic signaling involves molecules that support neuronal development, maintenance and plasticity.

Selank has been investigated in research involving neurochemical and gene-associated pathways.

Some discussions of Selank reference brain-derived neurotrophic factor (BDNF).

However, evidence for reliable, clinically meaningful BDNF enhancement in humans is insufficient.

Research Areas

Neurotrophic signaling

Neuronal adaptation

Gene expression

Synaptic-associated pathways

Cellular stress responses

Experimental neuroplasticity

Selank should not be described as a clinically proven neuroregenerative compound.

Selank and BDNF Research

BDNF is a neurotrophin involved in neuronal survival and synaptic function.

Experimental research into peptide signaling may examine BDNF-associated pathways.

However, a change in BDNF gene expression or concentration in a particular model does not necessarily establish improved cognition or mental health.

For Selank, direct and reproducible human evidence remains limited.

Selank and Cognitive Research

Selank has sometimes been described as a nootropic peptide.

The term nootropic generally refers to substances investigated or promoted for cognitive effects.

However, the label does not establish efficacy.

Experimental Research Areas

Learning-related behavior

Memory-associated tasks

Attention-related processes

Stress and cognition interactions

Neurotransmission

Neuroplasticity-associated signaling

Some preclinical studies have reported behavioral findings.

However, strong clinical evidence that Selank improves memory, attention or intelligence in healthy humans is lacking.

Selank and Memory Research

Memory depends on complex neural networks.

Researchers have investigated whether Selank influences learning-related experimental endpoints.

Potential mechanisms discussed include GABAergic and other neurochemical pathways.

However, human memory-enhancement claims remain unproven.

Selank should not be marketed as a clinically established memory enhancer.

Selank and Attention Research

Attention involves multiple interacting neural systems.

Selank has been discussed in relation to attention and mental performance.

However, there is insufficient high-quality clinical evidence establishing reliable attention-enhancing effects.

Experimental neurochemical findings do not automatically translate into improved cognitive performance.

Selank and Emotional Processing

Emotional processing involves neural circuits that integrate sensory, cognitive and physiological information.

Selank has been investigated in behavioral research associated with anxiety and stress.

Potential research areas include:

Emotional reactivity

Behavioral responses

Stress-associated processing

Neurotransmission

Neural network regulation

However, claims of improved emotional stability or resilience require stronger controlled human evidence.

Selank and Sleep Research

Selank is sometimes promoted for sleep improvement.

However, the evidence supporting these claims is limited.

Research Questions

Does Selank influence sleep-associated neural circuits?

Can GABA-related molecular effects alter sleep physiology?

Are any sleep-related outcomes reproducible?

Does Selank affect objective sleep architecture?

Are reported changes clinically meaningful?

Selank has not been established as an effective treatment for insomnia or other sleep disorders.

Selank and Depression Research

Depression involves multiple biological and psychosocial processes.

Selank has been studied primarily in anxiety-associated research contexts.

Some publications have examined immune or neurochemical markers in patient populations with psychiatric conditions.

However, Selank has not been established as an effective antidepressant treatment.

Evidence from anxiety-related studies should not be assumed to demonstrate efficacy for major depressive disorder.

Selank and Peptide Stability

Peptide stability is important in research chemistry.

Selank contains seven amino acids and a proline-rich C-terminal region.

Researchers have investigated the metabolic behavior of tuftsin-related peptides and their derivatives.

Research Topics

Proteolytic degradation

Peptide bond stability

Enzymatic metabolism

Fragment identification

Chemical degradation

Temperature-associated stability

Analytical recovery

Actual stability depends on the formulation and environmental conditions.

No universal storage, reconstitution or administration procedure should be assumed for all Selank products.

Selank vs. Tuftsin

Tuftsin is a naturally occurring immunoregulatory tetrapeptide.

Selank is a synthetic heptapeptide developed from tuftsin.

The two peptides are related but not interchangeable.

Selank vs. Semax

Selank and Semax are both synthetic heptapeptides associated with Russian peptide research.

However, their amino acid sequences and developmental origins differ.

The shared Pro–Gly–Pro motif does not establish identical biological effects.

Selank vs. Pinealon

Selank and Pinealon are structurally distinct peptides.

Selank: Thr–Lys–Pro–Arg–Pro–Gly–Pro

Pinealon: Glu–Asp–Arg

Results involving Pinealon cannot establish the effects of Selank.

Selank vs. Oxytocin

Oxytocin is an endogenous cyclic nonapeptide hormone.

Selank is a synthetic linear heptapeptide.

Oxytocin's established medical applications do not establish a therapeutic role for Selank.

Selank vs. KPV

Selank and KPV are different peptides with distinct research backgrounds.

Selank: TKPRPGP

KPV: Lys–Pro–Val

Their biological effects should not be assumed to overlap.

Selank Human Clinical Research

Selank has been evaluated in a small number of human clinical studies, primarily conducted in Russia.

Published investigations have examined anxiety-associated symptoms and related biological markers.

Reported Research Areas

Generalized anxiety disorder

Neurasthenia

Anxiety-associated symptoms

Psychometric measurements

Enkephalin metabolism

Immune-associated endpoints

Some studies reported improvements.

However, the evidence is not sufficient to establish broad clinical efficacy.

Major Limitations

Relatively small participant groups

Limited placebo-controlled evidence

Incomplete methodological reporting in accessible abstracts

Limited independent replication

Geographical concentration of research

Uncertain generalizability

Limited long-term safety information

These limitations are important when interpreting clinical claims.

Selank Regulatory Status

Selank has been used as a medicinal product in Russia.

However, regulatory authorization differs between countries.

United States

Selank is not an FDA-approved human therapeutic drug.

European Union

Selank does not have an EMA centralized marketing authorization.

Russia

Selank has been developed and used in a regional pharmaceutical context.

Research Products

A research-grade Selank preparation is not equivalent to an authorized pharmaceutical product.

The existence of regional medical use does not establish the safety or legality of administering research-grade material.

Selank Safety Considerations

The safety of Selank depends on the specific preparation, exposure conditions and population.

Available human safety data are limited.

Unknown Long-Term Safety

Large, independently replicated long-term safety studies are lacking.

Uncertain Pharmacokinetics

Human absorption, distribution, metabolism and elimination are not comprehensively characterized across formulations.

Incomplete Molecular Mechanism

The precise receptor targets and signaling mechanisms remain uncertain.

Potential Neurochemical Effects

Experimental interactions with neurotransmission-related systems require careful investigation.

Potential Immune-Associated Effects

Immune-related responses may vary across experimental conditions.

Product Quality Risks

Research-grade preparations may differ in peptide content, purity and manufacturing controls.

Unverified Clinical Benefits

Claims of improved anxiety, sleep, memory or mental performance are not supported by sufficiently strong international clinical evidence.

Unknown Interaction Profile

Potential interactions with other neuroactive substances have not been adequately characterized.

Research-grade Selank should not be used as a substitute for prescribed psychiatric or neurological treatment.

Selank Analytical Characterization

Accurate molecular identification is essential for scientific peptide research.

Important Specifications

Verified amino acid sequence

Molecular formula

Molecular mass

Terminal chemistry

Peptide purity

Peptide content

Counterion composition

Impurity profile

Residual reagents

Degradation products

Batch-specific documentation

High-Performance Liquid Chromatography

HPLC can help evaluate peptide purity and detect chromatographic impurities.

However, a purity percentage alone does not establish pharmaceutical quality.

Liquid Chromatography–Mass Spectrometry

LC-MS can support molecular identity verification.

For standard unmodified Selank, the expected molecular mass is approximately 751.89 g/mol.

The measured material should be consistent with the specified molecular form.

Peptide Content Analysis

Peptide content analysis helps distinguish the actual peptide quantity from the total mass of material.

This is relevant when a product contains counterions, residual water or other components.

Certificate of Analysis

A batch-specific COA should provide appropriate analytical information.

Relevant data may include:

• Product identity

• Batch or lot number

• Analytical methods

• Peptide purity

• Peptide content

• Molecular identity

• Impurity profile

• Counterion information

• Stability documentation

A COA does not establish clinical efficacy or authorization for human use.

Scientific Evidence and Research Limitations

Established Molecular Facts

• Selank is a synthetic seven-amino-acid peptide.

• Its sequence is Thr–Lys–Pro–Arg–Pro–Gly–Pro.

• Its molecular formula is C₃₃H₅₇N₁₁O₉.

• Its molecular weight is approximately 751.89 g/mol.

• It was developed from the tuftsin peptide sequence.

• It contains a Pro–Gly–Pro C-terminal extension.

• Laboratory studies have investigated GABA-associated binding.

• Animal studies have reported neurotransmission-related gene-expression changes.

• Limited human clinical studies have been published.

• Selank has a history of regional pharmaceutical use in Russia.

Important Limitations

• Its complete molecular mechanism remains uncertain.

• Large, independently replicated clinical trials are lacking.

• FDA approval has not been granted.

• EMA centralized authorization has not been granted.

• Human long-term safety is insufficiently characterized.

• Reliable cognitive enhancement has not been established.

• Clinical sleep benefits are unproven.

• General immune-enhancing effects are unproven.

• Gene-expression changes do not establish clinical efficacy.

• Findings involving pharmaceutical Selank do not validate research-grade products.

Potential Selank Research Applications

Selank may be relevant to appropriately controlled laboratory investigations involving:

• Tuftsin-derived peptide chemistry

• GABAergic neurotransmission

• GABA-associated receptor binding

• Allosteric modulation research

• Neurotransmission-related gene expression

• Anxiety-associated animal models

• Stress-response biology

• Enkephalin metabolism

• Neuropeptide-degrading enzymes

• Neuroimmune communication

• Cytokine-associated signaling

• IL-6-related experimental research

• Dopamine receptor gene expression

• Serotonin-associated signaling

• Behavioral neuroscience

• Experimental cognitive research

• Neurotrophic signaling

• Peptide stability

• Proteolytic degradation

• Structure–activity relationships

• Comparative peptide pharmacology

• Analytical method development

These are research applications, not established therapeutic benefits.

Selank Research Overview

Compound Name: Selank

Alternative Names: TP-7 / Selanc

Classification: Synthetic Linear Heptapeptide

Amino Acid Length: 7

Sequence: H-Thr-Lys-Pro-Arg-Pro-Gly-Pro-OH

One-Letter Sequence: TKPRPGP

Molecular Formula: C₃₃H₅₇N₁₁O₉

Molecular Weight: Approximately 751.89 g/mol

CAS Number: 129954-34-3

PubChem CID: 11765600

Parent Peptide: Tuftsin

Principal Research Areas: GABAergic Signaling / Neuroimmune Biology / Behavioral Neuroscience

Established Single Molecular Receptor: Not Conclusively Identified

Human Clinical Evidence: Limited Regional Studies

FDA/EMA Approval: No

Intended Research Use: Laboratory Research Only

ICAME Pharmacy Product Information

Product Name: Selank

Alternative Name: TP-7

Brand: ICAME Pharmacy

Product Category: Research Peptide

Research Classification: Synthetic Tuftsin-Derived Heptapeptide

Research Areas: Neuroscience / GABAergic Signaling / Neuroimmune Biology / Peptide Pharmacology

Intended Use: Laboratory Research & Development Only

Product identity and specifications should be verified using batch-specific analytical documentation.

Relevant quality information includes:

• Verified amino acid sequence

• Molecular identity

• Peptide purity

• Peptide content

• Counterion composition

• Impurity profile

• Analytical methodology

• Certificate of Analysis (COA)

• Batch or lot identification

• Validated stability and storage conditions

No claims of pharmaceutical quality, sterility, injectable suitability or clinical efficacy should be made without appropriate supporting documentation.

Important Research Use Notice

FOR RESEARCH USE ONLY (RUO)

This ICAME Pharmacy product is intended exclusively for legitimate laboratory, analytical and scientific research purposes.

Not for human or veterinary use. Not for diagnostic, therapeutic, psychiatric, neurological, cognitive enhancement, sleep improvement, performance-enhancing or other clinical purposes. Not for direct administration to humans or animals.

Selank is a synthetic heptapeptide investigated in experimental neuroscience, neuroimmune research and limited human clinical studies.

Its precise molecular mechanism, human pharmacokinetics, long-term safety and broad clinical efficacy have not been adequately established.

Regional medical use of Selank does not establish the suitability of research-grade Selank products for clinical administration.

Information presented on this page is intended solely for scientific and educational purposes and does not constitute medical advice, prescribing information, dosage guidance or instructions for human use.

About ICAME Pharmacy

ICAME Pharmacy provides specialized research products for professional laboratory and scientific applications.

Our portfolio focuses on compounds relevant to peptide science, neurobiology, molecular signaling, neuroimmune research and analytical chemistry.

We emphasize accurate product identification, responsible research use, scientific transparency and clear communication of evidence limitations.

For batch-specific analytical documentation and product inquiries, please contact ICAME Pharmacy.

Frequently Asked Questions About Selank

What is Selank?

Selank is a synthetic seven-amino-acid peptide derived from the endogenous immunoregulatory peptide tuftsin.

What is the alternative name for Selank?

TP-7 is a commonly used alternative designation.

How many amino acids does Selank contain?

Seven amino acids.

What is the amino acid sequence of Selank?

Thr–Lys–Pro–Arg–Pro–Gly–Pro.

What is the one-letter sequence of Selank?

TKPRPGP.

What is the molecular formula of Selank?

C₃₃H₅₇N₁₁O₉.

What is the molecular weight of Selank?

Approximately 751.89 g/mol.

What is the CAS number of Selank?

129954-34-3.

Is Selank a cyclic peptide?

No. Selank is a linear heptapeptide.

What is tuftsin?

Tuftsin is an endogenous tetrapeptide with the sequence Thr–Lys–Pro–Arg.

How is Selank related to tuftsin?

Selank contains the tuftsin sequence with an additional Pro–Gly–Pro extension.

What is Selank's mechanism of action?

Its complete mechanism is not established. Research has investigated GABA-associated binding, neurotransmission-related gene expression and enkephalin metabolism.

Does Selank act on GABA receptors?

Laboratory studies have reported changes in GABA-associated binding, but its precise receptor pharmacology remains incompletely characterized.

Does Selank work like a benzodiazepine?

Some experimental and clinical comparisons have been published, but Selank is not established as pharmacologically or clinically equivalent to benzodiazepines.

Has Selank been studied in humans?

Yes. Small human studies have been published, primarily in Russia.

Does Selank treat anxiety?

Some studies have reported improvements in anxiety-related outcomes, but high-quality independent confirmatory evidence remains limited.

Does Selank improve memory?

Strong clinical evidence establishing reliable memory enhancement is lacking.

Does Selank improve sleep?

Selank has not been established as an effective treatment for sleep disorders.

Is Selank an immune booster?

Immune-associated effects have been investigated, but generalized immune enhancement has not been clinically established.

Is Selank the same as Semax?

No. Selank is a tuftsin-derived peptide, while Semax is derived from an ACTH-related sequence.

Is Selank the same as Pinealon?

No. Selank is TKPRPGP, while Pinealon is EDR.

Is Selank approved by the FDA?

No. Selank is not an FDA-approved human therapeutic drug.

Is Selank approved in Europe?

Selank does not have EMA centralized marketing authorization.

Is Selank used as a medicine in Russia?

Yes. Selank has a history of regional pharmaceutical use in Russia.

Is research-grade Selank safe for human use?

Human safety has not been adequately established for research-grade preparations.

Is ICAME Pharmacy Selank intended for human use?

No. ICAME Pharmacy Selank is intended strictly for laboratory research and development purposes.